Dr. Michael F. Driscoll

Oncology
315 E Broadway, Fl 4, 
Louisville, KY 
Accepting New Patients
Offers Telehealth
315 E Broadway, Fl 4, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Driscoll is an Oncologist in Louisville, Kentucky. Dr. Driscoll is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lynch Syndrome. Dr. Driscoll is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Norton Hospitals, Inc
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

NORTON HOSPITALS, INC
315 E Broadway, Fl 4, Louisville, KY 40202
Other Locations
NORTON HOSPITALS, INC
2355 Poplar Level Rd, Suite 405, Louisville, KY 40217
NORTON HOSPITALS, INC
1 Audubon Plaza Dr, Louisville, KY 40217

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Journal: Annals of surgical oncology
Published: February 07, 2022
Similar Doctors
Advanced in Prothrombin Deficiency
Dr. Naveed M. Chowhan
Hematology Oncology | Oncology
Advanced in Prothrombin Deficiency
Dr. Naveed M. Chowhan
Hematology Oncology | Oncology

Jackson County Schneck Memorial Hospital

411 W Tipton St, Schneck Medical Center, 
Seymour, IN 
 (49.6 miles away)
812-522-2349
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naveed Chowhan is a Hematologist Oncology specialist and an Oncologist in Seymour, Indiana. Dr. Chowhan is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Non-Hodgkin Lymphoma, Congenital Antithrombin 3 Deficiency, and Bone Marrow Aspiration. Dr. Chowhan is currently accepting new patients.

Advanced in Prothrombin Deficiency
Dr. Ifeoma R. Okeke
Hematology Oncology | Oncology | Hematology
Advanced in Prothrombin Deficiency
Dr. Ifeoma R. Okeke
Hematology Oncology | Oncology | Hematology

Baptist Health Medical Group Inc

1373 E State Rd, 62 Louisville Cardiology G, 
Madison, IN 
 (43.1 miles away)
812-801-0810
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ifeoma Okeke is a Hematologist Oncology specialist and an Oncologist in Madison, Indiana. Dr. Okeke is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Hereditary Resistance to Anti-Vitamin K, and Congenital Antithrombin 3 Deficiency. Dr. Okeke is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Alfonso A. Cervera
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Alfonso A. Cervera
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

2210 Green Valley Rd, 
New Albany, IN 
 (6.3 miles away)
812-941-5714
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Alfonso Cervera is a Hematologist Oncology specialist and a Hematologist in New Albany, Indiana. Dr. Cervera is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Marginal Zone Lymphoma (MZL), Familial Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Cervera is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Driscoll's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 67 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile